AR088876A1 - FORMULACION COMPLEJA ORAL QUE COMPRENDE ACIDO GRASO OMEGA-3 Y UN INHIBIDOR DE LA HMG-CoA REDUCTASA CON ESTABILIDAD MEJORADA - Google Patents
FORMULACION COMPLEJA ORAL QUE COMPRENDE ACIDO GRASO OMEGA-3 Y UN INHIBIDOR DE LA HMG-CoA REDUCTASA CON ESTABILIDAD MEJORADAInfo
- Publication number
- AR088876A1 AR088876A1 ARP120104299A ARP120104299A AR088876A1 AR 088876 A1 AR088876 A1 AR 088876A1 AR P120104299 A ARP120104299 A AR P120104299A AR P120104299 A ARP120104299 A AR P120104299A AR 088876 A1 AR088876 A1 AR 088876A1
- Authority
- AR
- Argentina
- Prior art keywords
- complex formulation
- coating layer
- oral complex
- omega
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 13
- 238000009472 formulation Methods 0.000 title abstract 10
- 239000002253 acid Substances 0.000 title abstract 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011247 coating layer Substances 0.000 abstract 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 6
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 6
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 6
- 239000002775 capsule Substances 0.000 abstract 4
- 239000011248 coating agent Substances 0.000 abstract 4
- 238000000576 coating method Methods 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000007902 hard capsule Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007901 soft capsule Substances 0.000 abstract 2
- 239000000600 sorbitol Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 229920000578 graft copolymer Polymers 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical group [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960000672 rosuvastatin Drugs 0.000 abstract 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Reivindicación 1: Una formulación compleja oral, que comprende: (1) el núcleo de una cápsula que comprende una cápsula dura o blanda que contiene sorbitol, sorbitan y, como componente efectivo desde el punto de vista farmacéutico, un ácido graso omega-3; (2) una primera capa de recubrimiento que comprende un material de recubrimiento resistente al agua, dicha capa de recubrimiento se forma sobre la superficie del núcleo de la cápsula; y (3) una segunda capa de recubrimiento que comprende un inhibidor de la HMG-CoA reductasa y un estabilizador alcalino, dicha segunda capa de recubrimiento se forma sobre la superficie de la primera capa de recubrimiento. Reivindicación 5: La formulación compleja oral de la reivindicación 1, en donde dicho ácido graso omega-3 se selecciona del grupo que consiste en ácido graso omega-3 natural o sintetizado; ésteres aceptables desde el punto de vista farmacéutico, derivados, precursores o sales de los anteriores; y cualquier mezcla de los anteriores. Reivindicación 7: La formulación compleja oral de la reivindicación 5, en donde dicho ácido graso omega-3 se selecciona del grupo que consiste en ácido eicosapenta-5,8,11,14,17-enoico (ácido eicosapentanoico, EPA), docosahexa-4,7,10,13,16,19-enoico ácido (ácido docosahexaenoico, DHA), y/o ácido a-linolenico y precursores de los anteriores. Reivindicación 8: La formulación compleja oral de la reivindicación 1, en donde dicho ácido graso omega-3 se encuentra en una cantidad que oscila desde 70 hasta 95% en peso en base al peso total del núcleo de la cápsula. Reivindicación 10: La formulación compleja oral de la reivindicación 1, en donde dicho material de recubrimiento resistente al agua comprende celulosa de etilo. Reivindicación 12: La formulación compleja oral de la reivindicación 1, en donde dicho inhibidor de la HMG-CoA reductasa se selecciona del grupo que consiste en simvastatina, pravastatina, fluvastatina, atorvastatina, cerivastatina, rosuvastatina, pitavastatina, y las sales aceptables desde el punto de vista farmacéutico de los anteriores. Reivindicación 14: La formulación compleja oral de la reivindicación 1, en donde dicho estabilizante alcalino se selecciona del grupo que consiste en carbonato de magnesio (MgCO₃), carbonato ácido de sodio (NaHCO₃), hidróxido de magnesio (Mg(OH)₂), y una mezcla de los anteriores. Reivindicación 23: La formulación compleja oral de la reivindicación 1, en donde dicha segunda capa de recubrimiento comprende un material de recubrimiento seleccionado del grupo que consiste en hidroxipropilcelulosa de etilo, polivinilpirrolidona, polietilenglicol, copolímero de injerto de alcohol polivinílico-polietilenglicol, y una mezcla de los anteriores. Reivindicación 25: Un método para preparar la formulación compleja oral de la reivindicación 1, que comprende los pasos de: i) llenar una cápsula dura o blanda que comprende sorbitol y sorbitan con un ácido graso omega-3 para preparar el núcleo de una cápsula; ii) formar una primera capa de recubrimiento que comprende un material de recubrimiento resistente al agua sobre la superficie del núcleo; y iii) formar una segunda capa de recubrimiento que comprende un inhibidor de la HMG-CoA reductasa y un estabilizador alcalino sobre la superficie de la primera capa de recubrimiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110120493 | 2011-11-17 | ||
| KR1020120128926A KR101466617B1 (ko) | 2011-11-17 | 2012-11-14 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088876A1 true AR088876A1 (es) | 2014-07-16 |
Family
ID=48663604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104299A AR088876A1 (es) | 2011-11-17 | 2012-11-15 | FORMULACION COMPLEJA ORAL QUE COMPRENDE ACIDO GRASO OMEGA-3 Y UN INHIBIDOR DE LA HMG-CoA REDUCTASA CON ESTABILIDAD MEJORADA |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140314844A1 (es) |
| EP (1) | EP2780002A4 (es) |
| JP (1) | JP6073352B2 (es) |
| KR (1) | KR101466617B1 (es) |
| CN (1) | CN103957896A (es) |
| AR (1) | AR088876A1 (es) |
| HK (1) | HK1199396A1 (es) |
| SA (1) | SA112340005B1 (es) |
| TW (1) | TW201328727A (es) |
| UY (1) | UY34455A (es) |
| WO (1) | WO2013073884A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101752700B1 (ko) * | 2014-08-13 | 2017-07-03 | 한국유나이티드제약 주식회사 | 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제 |
| TWI525110B (zh) * | 2014-12-24 | 2016-03-11 | 財團法人工業技術研究院 | 聚合物、及包含其之醫藥組合物 |
| WO2017171484A1 (ko) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
| KR102108154B1 (ko) * | 2017-02-08 | 2020-05-07 | (주)동구바이오제약 | 개선된 생체이용률을 갖는 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| DE3307353C2 (de) * | 1983-03-02 | 1985-01-31 | R.P. Scherer GmbH, 6930 Eberbach | Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung |
| GB8305693D0 (en) * | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US4963385A (en) * | 1989-06-02 | 1990-10-16 | Nabisco Brands, Inc. | Stabilized emulsions containing highly unsaturated oils |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| DE69324504T2 (de) * | 1993-01-19 | 1999-08-26 | Warner-Lambert Co. | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| GB9706149D0 (en) * | 1997-03-25 | 1997-05-14 | Scherer Corp R P | Comestible capsules having flavoured coatings |
| WO2001093860A1 (en) * | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
| AU2005314361B2 (en) * | 2004-12-06 | 2012-04-12 | Glaxosmithkline Llc | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
| EP2081550B2 (en) * | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
| NZ573910A (en) * | 2006-06-16 | 2011-07-29 | Cipla Ltd | Dry powder inhaler in which the turbulent flow causes the vibration of capsule assisting in release of medicament |
| ITFI20060162A1 (it) * | 2006-06-26 | 2007-12-27 | Valpharma Sa | Composizione farmaceutica per la somministrazione orale di acidi grassi omega polienoici ed uno o piu' principi attivi con essi incompatibili, e processo per la sua preparazione. |
| JP2009541433A (ja) | 2006-06-26 | 2009-11-26 | ヴァルファルマ ソチエタ アノニマ | オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び１又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程 |
| CA2711814A1 (en) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Capsule formulation |
| KR20090091083A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 방출성이 제어된 심혈관계질환 치료용 약제학적 제제 |
| CN102307464A (zh) * | 2008-12-31 | 2012-01-04 | 尼特罗米加公司 | 含有硝基脂肪酸的营养制品 |
| EP3181131A1 (en) * | 2009-05-22 | 2017-06-21 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying compositin of 3 fatty acid |
-
2012
- 2012-11-14 KR KR1020120128926A patent/KR101466617B1/ko active Active
- 2012-11-15 AR ARP120104299A patent/AR088876A1/es unknown
- 2012-11-16 TW TW101142820A patent/TW201328727A/zh unknown
- 2012-11-16 US US14/358,853 patent/US20140314844A1/en not_active Abandoned
- 2012-11-16 JP JP2014542243A patent/JP6073352B2/ja not_active Expired - Fee Related
- 2012-11-16 CN CN201280056897.9A patent/CN103957896A/zh active Pending
- 2012-11-16 WO PCT/KR2012/009718 patent/WO2013073884A1/en not_active Ceased
- 2012-11-16 HK HK14112885.7A patent/HK1199396A1/xx unknown
- 2012-11-16 EP EP12850234.1A patent/EP2780002A4/en not_active Withdrawn
- 2012-11-16 UY UY0001034455A patent/UY34455A/es not_active Application Discontinuation
- 2012-11-17 SA SA112340005A patent/SA112340005B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014533685A (ja) | 2014-12-15 |
| CN103957896A (zh) | 2014-07-30 |
| JP6073352B2 (ja) | 2017-02-01 |
| US20140314844A1 (en) | 2014-10-23 |
| KR20130054921A (ko) | 2013-05-27 |
| UY34455A (es) | 2013-06-28 |
| HK1199396A1 (en) | 2015-07-03 |
| KR101466617B1 (ko) | 2014-11-28 |
| EP2780002A4 (en) | 2015-05-27 |
| TW201328727A (zh) | 2013-07-16 |
| WO2013073884A1 (en) | 2013-05-23 |
| EP2780002A1 (en) | 2014-09-24 |
| SA112340005B1 (ar) | 2015-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085547A1 (es) | Composicion compleja oral que comprende ester del acido graso omega-3 y un inhibidor de la hmg-coa reductasa | |
| AR082930A1 (es) | Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina | |
| ES2539861T3 (es) | Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos | |
| ES2710540T3 (es) | Preparación de compuesto de ácido graso omega-3 | |
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| AR088876A1 (es) | FORMULACION COMPLEJA ORAL QUE COMPRENDE ACIDO GRASO OMEGA-3 Y UN INHIBIDOR DE LA HMG-CoA REDUCTASA CON ESTABILIDAD MEJORADA | |
| PE20140163A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| JP2013538814A5 (es) | ||
| AR095182A1 (es) | Composiciones de estatinas y ácidos grasos omega-3 | |
| PE20131101A1 (es) | Formulaciones estables al almacenamiento de oxicodona y naloxona | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| AR074391A1 (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
| DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| CO6290635A2 (es) | Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua | |
| RU2011139638A (ru) | Сублингвальная фармацевтическая композиция, содержащая нейтральное масло | |
| RU2017129161A (ru) | Композиции липидов | |
| PT2853263T (pt) | Forma de revestimento em múltiplas camadas de composição farmacêutica administrada por via oral contendo ácido gordo ómega-3 ou seu éster alquílico e fármaco à base de estatina | |
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| ES2720869T3 (es) | Composiciones farmacéuticas de sevelámero | |
| WO2009059717A3 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| AR101724A1 (es) | COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA | |
| AR080023A1 (es) | Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa | |
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir | |
| RU2016103087A (ru) | Комбинированная композиция, содержащая метформин замедленного высвобождения и ингибитор HMG-CoA-редуктазы немедленного высвобождения | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |